Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3][4]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.055.494 |
Chemical and physical data | |
Formula | C21H27N |
Molar mass | 293.454 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |
While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[5][6] but also promoting the synthesis of dopamine.[7]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[7][8]
Budipine can be prepared from the 1-tert-butyl-4-piperidone [1465-76-5] directly by treatment with benzene in the presence triflic acid.[9] This method of synthesis enables a 99% yield of product.
4-Phenyl-1-t-butyl-4-piperidinol,[11] (1)
1-t-butyl-3-benzoyl-4-phenyl-4-piperidinol [81831-81-4] (3)
{{cite book}}
: |journal=
ignored (help)